ACKR3 / Atypical chemokine receptor 3 · IHC design guide

Design Immunohistochemistry for ACKR3

Plan chromogenic ACKR3 IHC in paraffin sections with the catalog antibody at 2–5 µg/ml (datasheet A02656-2). Score variable cytoplasmic staining in trophoblasts and immune cells, bearing in mind the reported low consistency between staining and RNA expression (HPA tissue IHC).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for ACKR3 (IHC for ACKR3): expected localisation Cytoplasmic staining in tissue (HPA tissue IHC), antibody A02656-2, validated IHC image, and IHC protocol steps — Printable **ACKR3** IHC protocol sheet — expected localisation Cytoplasmic staining in tissue (HPA tissue IHC), antibody A02656-2, controls and protocol steps. Open the full ACKR3 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

ACKR3 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining in tissue (HPA tissue IHC)
	Staining pattern	Variable cytoplasmic staining in trophoblasts and immune cells (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet A02656-2)
	Positive control ⓘ	Appendix+4 more · see all
	Negative control ⓘ	Adrenal gland+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific)
	Caveat	Staining shows low consistency with RNA expression (HPA tissue IHC)
	Regulation	Ligand-induced internalization may shift staining to vesicles (UniProt)
	Isoform / epitope	No isoforms annotated; map epitopes to extracellular or cytoplasmic regions (UniProt)

Section 1

Recommended ACKR3 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet A02656-2) appears alongside two published ACKR3 chromogenic IHC protocols (PMC10523940; PMC6274818).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A02656-2)
Fixation	Image fixative and duration unreported (datasheet A02656-2); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet A02656-2); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A02656-2)
Primary antibody	Rabbit anti-ACKR3, 2-5 µg/ml (datasheet A02656-2)
Primary incubation	Overnight at 4 °C (datasheet A02656-2)
Detection	HRP-conjugated secondary, DAB chromogen (datasheet A02656-2)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	ACKR3-positive staining in lymphoid tissue of appendix (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression at variable levels in several different cell types, including trophoblasts and immune cells. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet A02656-2); citrate pH 6 is a published alternative for breast carcinoma sections (PMC6274818).

Section 2

What Is the Expected ACKR3 Staining Pattern?

ACKR3 is a seven-pass membrane receptor that predominantly occupies endocytic vesicles and can recycle to the cell surface (UniProt P25106 topology and subcellular location). In paraffin-section IHC, expect cytoplasmic staining in selected cells, including kidney tubular and placental trophoblastic cells (HPA: Medium; tissue profile). HPA rates the tissue IHC evidence Approved but reports low consistency between staining and RNA expression (HPA: reliability description).

What am I looking at on my slide?
Granular cytoplasmic staining in kidney tubular cells or placental trophoblastic cells, with possible membrane accentuation.	This fits HPA's Medium staining in those cells and its variable cytoplasmic tissue profile (HPA: kidney, placenta, tissue profile). A membrane component is biologically plausible, while prominent intracellular puncta fit ACKR3's predominant endocytic-vesicle location (UniProt P25106 subcellular location). Judge the cell population and compartment together; intensity alone cannot establish specificity (HPA: low staining–RNA consistency).
Predominantly nuclear staining, without a convincing cytoplasmic or cell-border component.	A nuclear-only pattern does not match the reported cell membrane, early endosome, and recycling endosome locations (UniProt P25106 subcellular location). Treat it as suspect staining and compare with a matched negative control and tissue architecture before assigning ACKR3 positivity (general IHC practice).
Strong staining throughout a cell population listed as Not detected, or uniform staining of unrelated structures.	For example, HPA reports Not detected in adrenal glandular cells and bone-marrow hematopoietic cells (HPA: adrenal gland, bone marrow). Broad signal there raises possible cross-reactivity or endogenous detection activity (general IHC practice). It is a warning, not proof of either cause: HPA's Approved tissue stain has low consistency with RNA data (HPA: reliability description).
Diffuse color across tissue, stroma, and empty regions, obscuring individual cells.	That distribution cannot be read as the cell-associated cytoplasmic pattern reported by HPA (HPA: tissue profile). Uneven blocking, detection-system activity, or excess antibody are general IHC possibilities (general IHC practice). Reassess the run with appropriate control sections before interpreting focal staining (general IHC practice).
No convincing staining in an expected positive tissue section.	Kidney tubular and placental trophoblastic cells were reported at Medium intensity, so they are reasonable comparison populations (HPA: kidney, placenta). Absence can reflect assay performance, tissue variation, or the limited agreement between HPA staining and RNA expression; it does not by itself establish biological absence (HPA: reliability description; general IHC practice).

💡Expected ACKR3 appearanceCall a section positive when selected kidney tubular or placental trophoblastic cells show discernible Medium, chiefly cytoplasmic staining with possible membrane signal (HPA: kidney, placenta, tissue profile; UniProt P25106 subcellular location); isolated nuclear color or diffuse tissue-wide color is suspect (UniProt P25106 subcellular location; general IHC practice).

How each factor affects the staining
Compartment and receptor traffic	ACKR3 has 7 transmembrane segments and extracellular and cytoplasmic loops (UniProt P25106 topology). It is predominantly endocytic and recycles after ligand-induced internalization (UniProt P25106 subcellular location). Thus intracellular puncta and membrane staining can coexist; neither pattern alone measures receptor activity (UniProt P25106 function and subcellular location).
Tissue and cell selection	HPA reports Medium staining in kidney tubular, placental trophoblastic, pancreatic exocrine, and thyroid glandular cells, among others (HPA: tissue IHC). Lung macrophages are Low, and several sampled cell populations are Not detected (HPA: tissue IHC). Choose comparison areas by identified cell type, since whole-section intensity can hide that distribution (general IHC practice).
Evidence and antibody application	The tissue IHC profile is Approved but has low staining–RNA consistency (HPA: reliability description). HPA049718 is listed as IHC Approved; HPA032003 is listed as ICC Supported, with no IHC status supplied for that antibody (HPA: antibodies). These labels support application-specific interpretation but do not make every stained cell independently confirmed (HPA: antibody validation; reliability description).
Epitope interpretation	ACKR3 has extracellular N-terminal residues 1–40, a cytoplasmic C-terminal segment 320–362, and three annotated glycosylation sites near the N terminus (UniProt P25106 topology and glycosylation). An antibody's epitope would be needed to assess whether these features matter to its binding; no epitope or target-specific fixation effect is supplied (UniProt P25106 topology; supplied evidence scope).

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
No color in a kidney tubular or placental trophoblastic comparison area (HPA: Medium).	The run may have inadequate detection, or that specimen may differ from HPA's observation (general IHC practice; HPA: low staining–RNA consistency).	Check a run control, section quality, retrieval, and detection reagents using the validated IHC workflow; compare cell populations before calling the sample negative (general IHC practice).
Nuclear signal dominates the section.	Nuclear-only staining conflicts with ACKR3's reported membrane and endosomal locations (UniProt P25106 subcellular location).	Inspect a matched negative control and review antibody concentration and detection conditions; score nuclear-only color as unconfirmed (general IHC practice).
Diffuse brown background prevents cell-level scoring.	Non-cell-specific deposition can arise from antibody concentration, blocking, washing, or endogenous detection activity (general IHC practice).	Use appropriate negative and detection controls; optimize blocking, washes, and antibody dilution within the validated IHC workflow (general IHC practice).
Strong signal appears in an HPA Not detected cell population, such as adrenal glandular cells (HPA: adrenal gland).	Cross-reactivity or endogenous detection activity is possible, while HPA's low staining–RNA consistency limits a definitive judgment (general IHC practice; HPA: reliability description).	Compare morphology and controls, then seek independent confirmation before assigning ACKR3 to that population (general IHC practice).
Only a membrane rim is visible, with little cytoplasmic staining.	Membrane localization is reported, but ACKR3 predominantly localizes to endocytic vesicles (UniProt P25106 subcellular location).	Check whether the rim follows individual cell boundaries and whether expected positive cell populations are involved; do not reject a controlled result solely for lacking puncta (general IHC practice; HPA: tissue IHC).
IF/ICC Q: Should a vesicular signal be considered compatible with ACKR3?	HPA lists vesicles as Approved and plasma membrane as Supported in ICC-IF images from HeLa and U2OS (HPA: subcellular; cell lines).	Yes: interpret vesicular signal alongside membrane staining and cell controls (HPA: subcellular; general IF practice). Use the separate IF/ICC guide for that application; HPA032003 is ICC Supported (HPA: antibodies).

Source: UniProt P25106 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing ACKR3 staining

IHC analysis of GPCR RDC1/CXCR-7/ACKR3 using anti-GPCR RDC1/CXCR-7/ACKR3 antibody (A02656-2). GPCR RDC1/CXCR-7/ACKR3 was detected in a paraffin-embedded section of human breast cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-GPCR RDC1/CXCR-7/ACKR3 Antibody (A02656-2) overnight at 4°C. Peroxidase Conjugated Goat Anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB as the chromogen.

A02656-2 · IHCIHC analysis of GPCR RDC1/CXCR-7/ACKR3 using anti-GPCR RDC1/CXCR-7/ACKR3 antibody (A02656-2). GPCR RDC1/CXCR-7/ACKR3 was detected in a paraf

A30784 · IFImmunofluorescence analysis of COS7 cells, using CXCR7 Antibody. The picture on the right is blocked with the synthesized peptide.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000144476-ACKR3/tissue/cerebral+cortex#imid_14334604

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000144476-ACKR3/tissue/colon#imid_14334514

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000144476-ACKR3/tissue/liver#imid_14334515

HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000144476-ACKR3/tissue/pancreas#imid_14334466

HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA032003; green = ACKR3, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for ACKR3 IHC & IF

🧪Run kidney first: cells in tubules should stain (HPA: Medium in kidney tubular cells). Use adrenal glandular cells as a negative tissue (HPA: Not detected in adrenal glandular cells); on the kidney slide, compare tubular staining with adjacent nontubular cells as an internal background reference, without assuming those cells lack ACKR3.

Positive control tissue: Appendix (Lymphoid tissue, HPA Medium)

Negative control tissue: Adrenal gland (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ACKR3 in HeLa, U2OS, with annotated localisation: Vesicles (approved), Plasma membrane (supported) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only control and a rabbit host- and isotype-matched control, matching clonality if known; use ACKR3 knockout tissue or a validated peptide block as a biological specificity control (A02656-2 tissue-IHC caption: rabbit primary; standard IHC control practice). Quench endogenous peroxidase and inspect kidney tubules for pigment that could mimic DAB staining (A02656-2 tissue-IHC caption: HRP/DAB detection; standard IHC practice).

⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected paraffin-section caption does not state the fixative (A02656-2 tissue-IHC caption). The caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required (A02656-2 tissue-IHC caption). There is no supplied evidence that frozen sections or IF are easier; interpret kidney tubular signal against possible endogenous peroxidase and pigment background (HPA: Medium in kidney tubular cells; standard IHC practice).

HPA tissue IHC evidence for ACKR3

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Appendix	Lymphoid tissue	Medium	Protein (IHC)	HPA →
Bronchus	Ciliated cells (ciliary rootlets)	Medium	Protein (IHC)	HPA →
Fallopian tube	Ciliated cells (cell body)	Medium	Protein (IHC)	HPA →
Kidney	Cells in tubules	Medium	Protein (IHC)	HPA →
Pancreas	Exocrine glandular cells	Medium	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Caudate	Glial cells	Not detected	Protein (IHC)	HPA →
Cerebellum	Cells in granular layer	Not detected	Protein (IHC)	HPA →
Cerebral cortex	Endothelial cells	Not detected	Protein (IHC)	HPA →

Section 3

Advanced ACKR3 IHC Tips

Troubleshoot ACKR3 staining in paraffin sections by checking retrieval, compartment, cell identity, and controls before comparing signal across samples.

Which retrieval conditions should I try when ACKR3 staining is weak?

Start with heat mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A02656-2). The selected breast cancer section was stained after that retrieval, followed by 2 μg/ml primary antibody overnight at 4°C; the caption gives no retrieval duration (datasheet A02656-2). If staining is weak, vary heating time on adjacent sections while keeping the antibody concentration and detection steps fixed, and check tissue integrity after cooling (standard IHC practice). Interpret any gain against matched background and compartment controls, since ACKR3 can appear at the cell membrane and in endocytic vesicles (UniProt P25106 localization).

Could fixation explain weak or uneven ACKR3 staining?

The selected image is from a paraffin embedded breast cancer section, but its caption does not state the fixative or fixation duration (datasheet A02656-2). Target specific fixation sensitivity is therefore unknown; record fixation history for each specimen without treating a change in staining as an established ACKR3 effect (datasheet A02656-2). For troubleshooting, compare sections with documented, consistent processing while holding EDTA pH 8.0 retrieval and antibody conditions constant (datasheet A02656-2; standard IHC practice). Examine morphology and staining at tissue edges before adjusting retrieval, because processing variation can alter apparent signal and background in chromogenic IHC (standard IHC practice).

Should ACKR3 appear on the surface or inside cells?

Score membrane and punctate cytoplasmic staining separately: ACKR3 is annotated at the cell membrane, early endosomes, and recycling endosomes, with predominant localization to endocytic vesicles (UniProt P25106 localization). Ligand exposure can promote beta arrestin dependent internalization through clathrin coated pits, followed by receptor recycling (UniProt P25106 localization). The HPA subcellular profile likewise reports vesicles and plasma membrane, while its tissue IHC profile describes variable cytoplasmic staining (HPA subcellular; HPA tissue IHC). Compare the same cell compartment across sections, and investigate diffuse nuclear or acellular DAB deposits with morphology and controls before assigning them to ACKR3 (UniProt P25106 localization; standard IHC practice).

How can epitope location affect ACKR3 staining in paraffin sections?

ACKR3 has 7 annotated transmembrane segments and extracellular, cytoplasmic, and membrane embedded regions, so antibody accessibility depends on the mapped epitope (UniProt P25106 topology). Its extracellular N terminus contains glycosylation sites at residues 13, 22, and 39, while the cytoplasmic tail includes phosphoserines at 347, 350, and 355 (UniProt P25106 glycosylation; UniProt P25106 modified residues). No isoforms are listed in the supplied record, and the selected caption does not map this antibody’s epitope (UniProt P25106 isoforms; datasheet A02656-2). Request epitope information before attributing retrieval sensitivity or a compartment specific pattern to glycosylation, phosphorylation, or an isoform (standard IHC practice).

How should I investigate a matching ACKR3 pattern by immunofluorescence?

Treat IF as a separate validation experiment: the selected product caption describes chromogenic staining of a paraffin section, with no IF conditions (datasheet A02656-2). Multiplex ACKR3 with a marker for the cell population under study, such as an endothelial marker when assessing vascular staining, because endothelial expression is reported for ACKR3 (UniProt P25106 tissue specificity; standard IF practice). Choose fluorophores and controls that let you distinguish signal from tissue autofluorescence, and inspect single channel images before interpreting overlap (standard IF practice). Set permeabilisation after confirming whether the antibody recognizes an extracellular or cytoplasmic epitope; its epitope is unspecified, while ACKR3 spans the membrane 7 times (datasheet A02656-2; UniProt P25106 topology; standard IF practice).

What should I check when DAB background obscures ACKR3 staining?

Use a section processed without primary antibody to assess detection reagent and endogenous enzyme contributions, and inspect tissue edges and damaged areas separately (standard IHC practice). A peroxidase block and careful DAB development are general chromogenic IHC measures, not evidence that ACKR3 itself causes background (standard IHC practice). The selected section used 10% goat serum, 2 μg/ml rabbit primary overnight at 4°C, and a peroxidase conjugated secondary for 30 minutes at 37°C (datasheet A02656-2). If background persists, adjust blocking, washing, primary concentration, or development one factor at a time while checking whether membrane or vesicular staining remains distinguishable (UniProt P25106 localization; standard IHC practice).

How should I quantify ACKR3 across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and compartment before scoring, then record the percentage of positive cells and an intensity based H score for that population (standard IHC practice). Score membrane and vesicular or cytoplasmic signal separately because both locations are reported for ACKR3 (UniProt P25106 localization; HPA subcellular). For a spatial question, report positive cell density per mm² of viable tissue or a defined compartment, with area measured consistently across sections (standard IHC practice). Normalize counts to the relevant cell population or sampled viable area, and keep retrieval, exposure to DAB, thresholds, and reader criteria consistent across groups (standard IHC practice).

How can I distinguish convincing ACKR3 positivity from an artefact?

A convincing result has signal in identifiable cells with membrane or vesicular staining, supported by appropriate controls and morphology (UniProt P25106 localization; standard IHC practice). Compare cell identity with context: kidney tubular cells show medium HPA staining, whereas adrenal glandular cells are reported as not detected (HPA tissue IHC). Investigate nuclear only deposits, staining confined to cut edges or necrotic areas, and signal persisting without primary antibody before calling a sample positive; endogenous peroxidase can contribute to DAB signal (UniProt P25106 localization; standard IHC practice). Treat a positive pattern as provisional when it conflicts with other evidence, since HPA rates tissue IHC as approved but reports low consistency with RNA expression (HPA tissue IHC).

Boster reagents

Best ACKR3 / Atypical chemokine receptor 3 IHC Antibodies

The catalog shows ACKR3 staining in human paraffin tumor sections (A02656-2 IHC captions) and COS7 cells (A30784 IF caption); listed antibody reactivity spans human, monkey, mouse and rat (catalog reactivity).

Real IHC data

Anti-GPCR RDC1/CXCR-7/ACKR3 Antibody ®

Cat # A02656-2

View product →

Real IF data Immunofluorescence analysis of COS7 cells, using CXCR7 Antibody. The picture on the right is blocked with the synthesized peptide.

Anti-CXCR7 ACKR3 Antibody

Cat # A30784

View product →

A02656-2 lists human IHC and shows staining in paraffin-embedded human breast cancer, colon adenocarcinoma, endometrial cancer and urothelial carcinoma sections (A02656-2 applications, reactivity and IHC captions). A30784 lists IF/ICC and shows IF staining of COS7 cells with peptide blocking; its listed reactivity is human, monkey, mouse and rat (A30784 applications, IF caption and reactivity).

Which to pick: For tissue IHC, choose A02656-2: its IHC captions document human paraffin sections with EDTA retrieval at pH 8.0 and 2 µg/ml primary antibody; the fixative is unreported (A02656-2 IHC captions). For IF/ICC, choose A30784, which lists both applications and an IF dilution of 1:200–1:1000 (A30784 applications and datasheet). For cross-species IF/ICC, A30784 lists human, monkey, mouse and rat reactivity, while A02656-2 lists human only; both antibodies are rabbit polyclonal (catalog reactivity and dilution_raw).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P25106 (ACKR3_HUMAN, Atypical chemokine receptor 3).
Human Protein Atlas. ACKR3 tissue IHC expression (reliability: Approved).
Human Protein Atlas. ACKR3 subcellular location (ICC-IF): Localized to the plasma membrane and vesicles..
Human Protein Atlas. ACKR3 antibody validation summary (2 antibodies).
CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. Journal of clinical pathology 2022 — PMC9046756.
Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer. Cancer medicine 2023 — PMC10523940.
Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12. International journal of molecular sciences 2018 — PMC6274818.
Constructing a chemokine-based model and identifying CCL17 as a core biomarker associated with immune infiltrates in thyroid cancer. Translational cancer research 2025 — PMC12554474.
PubMed PMID:1675791 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:15815621 — UniProt-cited evidence.